Ankur A Patel1, Max Zhukosvky2, Shawn Sidharthan3, Rohan Jotwani2, Neal Rakesh4, Amitabh Gulati5. 1. Department of Physical Medicine & Rehabilitation, New York-Presbyterian Hospital/Columbia University Vagelos College of Physicians & Surgeons & Weill Medical College of Cornell University, New York, NY 10065, USA. 2. Department of Anesthesiology, New York-Presbyterian/Weill Medical College of Cornell University, New York, NY 10065, USA. 3. Department of Neurology, North Shore - Long Island Jewish Health System, Manhasset, NY 11030, USA. 4. Weill Cornell Tri-Institutional Pain Medicine Program, Department of Anesthesiology, Weill Medical College of Cornell University, New York, NY 10065, USA. 5. Department of Anesthesiology & Critical Care, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA.
Abstract
Aim: To evaluate the effectiveness of low-intensity focused ultrasound (LIFU) therapy in the management of cancer-related neuropathic pain (CNP). Methods: A retrospective review with 22 patients with CNP treated with LIFU therapy (frequency 3 Hz, 3 W/cm2, pulse mode duty cycle 50%) was conducted. Results: Out of the 22 patients, 15 had CNP secondary to chemotherapy-induced peripheral neuropathy. Compared with baseline, there was a significant reduction in numeric pain rating scale (p < 0.001). Additionally, 76.5% of patients (n = 13) were considered to be responders to LIFU therapy. Conclusion: LIFU therapy may be a viable treatment modality in the management of CNP, specifically chemotherapy-induced peripheral neuropathy, with a minimal side effect profile. Larger, prospective studies with a structured protocol are necessary.
Aim: To evaluate the effectiveness of low-intensity focused ultrasound (LIFU) therapy in the management of cancer-related neuropathic pain (CNP). Methods: A retrospective review with 22 patients with CNP treated with LIFU therapy (frequency 3 Hz, 3 W/cm2, pulse mode duty cycle 50%) was conducted. Results: Out of the 22 patients, 15 had CNP secondary to chemotherapy-induced peripheral neuropathy. Compared with baseline, there was a significant reduction in numeric pain rating scale (p < 0.001). Additionally, 76.5% of patients (n = 13) were considered to be responders to LIFU therapy. Conclusion: LIFU therapy may be a viable treatment modality in the management of CNP, specifically chemotherapy-induced peripheral neuropathy, with a minimal side effect profile. Larger, prospective studies with a structured protocol are necessary.
Authors: Ronald Bauer; Ernst Martin; Stefan Haegele-Link; Georg Kaegi; Moritz von Specht; Beat Werner Journal: Parkinsonism Relat Disord Date: 2014-01 Impact factor: 4.891
Authors: Ravi D Rao; Patrick J Flynn; Jeff A Sloan; Gilbert Y Wong; Paul Novotny; David B Johnson; Howard M Gross; Samer I Renno; Mohammed Nashawaty; Charles L Loprinzi Journal: Cancer Date: 2008-06-15 Impact factor: 6.860
Authors: Daniel Ciampi de Andrade; Manoel Jacobsen Teixeira; Ricardo Galhardoni; Karine S L Ferreira; Paula Braz Mileno; Nathalia Scisci; Alexandra Zandonai; William G J Teixeira; Daniel F Saragiotto; Valquíria Silva; Irina Raicher; Rubens Gisbert Cury; Ricardo Macarenco; Carlos Otto Heise; Mario Wilson Iervolino Brotto; Alberto Andrade de Mello; Marcelo Zini Megale; Luiz Henrique Curti Dourado; Luciana Mendes Bahia; Antonia Lilian Rodrigues; Daniella Parravano; Julia Tizue Fukushima; Jean-Pascal Lefaucheur; Didier Bouhassira; Evandro Sobroza; Rachel P Riechelmann; Paulo M Hoff; Fernanda Valério da Silva; Thais Chile; Camila S Dale; Daniela Nebuloni; Luiz Senna; Helena Brentani; Rosana L Pagano; Ângela M de Souza Journal: Oncologist Date: 2017-06-26
Authors: Susanna B Park; David Goldstein; Arun V Krishnan; Cindy S-Y Lin; Michael L Friedlander; James Cassidy; Martin Koltzenburg; Matthew C Kiernan Journal: CA Cancer J Clin Date: 2013 Nov-Dec Impact factor: 508.702